<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074425</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 035</org_study_id>
    <secondary_id>10065</secondary_id>
    <nct_id>NCT00074425</nct_id>
    <nct_alias>NCT00197665</nct_alias>
  </id_info>
  <brief_title>BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women</brief_title>
  <official_title>Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>HIV Prevention Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The majority of HIV infected people worldwide became infected with the virus through
      heterosexual contact. BufferGel and PRO 2000 Gel are vaginal gels designed to prevent women
      from becoming infected with HIV during sexual intercourse with an HIV infected partner. This
      study will test the safety and effectiveness of these gels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accessible, usable, and effective vaginal microbicides could significantly decrease the
      spread of HIV. Vaginal microbicides could be used with condoms to prevent HIV infection; they
      could also be used in situations in which an individual is unable to negotiate condom use.
      Vaginal microbicides are potentially bidirectional, preventing both male-to-female and
      female-to-male HIV transmission. This study will evaluate the safety and effectiveness of two
      vaginal microbicides, BufferGel and PRO 2000/5, in preventing the transmission of HIV. The
      study will also evaluate the effectiveness of these gels in preventing other common sexually
      transmitted infections (STIs).

      BufferGel is a buffering agent designed to maintain normal vaginal acidity in the presence of
      ejaculate. Studies have shown that HIV is inactivated below a pH of 4 to 5.8. Carbopol 974,
      the major nonaqueous component of BufferGel, is commonly used as a gelling or tableting agent
      and has a well-documented safety record. BufferGel has proven safe and well tolerated in
      Phase I studies. PRO 2000/5 inhibits viral entry into susceptible cells. PRO 2000/5 has also
      been evaluated in Phase I studies and was found to be safe and well tolerated.

      Participants in this study will be randomly assigned to receive one of four interventions:
      BufferGel, PRO 2000/5, placebo gel, or no gel. All participants will receive HIV risk
      reduction counseling, condoms, and diagnosis and treatment of sexually transmitted diseases.
      Participants in the three gel arms will be given single-use, prefilled applicators of gel and
      will be instructed to apply one dose of the product (BufferGel, PRO 2000/5, or placebo gel)
      intravaginally up to 60 minutes before each vaginal intercourse while in the study.

      Participants will be enrolled for approximately 12 to 30 months, depending on when they enter
      the study. Participants will have two screening study visits and then monthly visits. Monthly
      study visits may take place at a clinic, the participant's home, or other community site.
      Monthly visits will include a medical interview; urine testing, including pregnancy testing;
      HIV and sexually transmitted infection risk reduction counseling; and distribution of study
      supplies (condoms and gel-filled applicators). Blood collection will occur at selected
      monthly visits. Four times a year, participants will be seen in the clinic for a more
      structured medical interview, pelvic exam, and HIV testing. At one of these visits,
      participants at particular sites who are willing will be asked to complete a behavioral risk
      assessment. At some visits vaginal fluid swabs will occur. Participants at non-US study sites
      will be asked for permission for these swabs to be stored for further testing. Assessment
      interviews will be both face to face and self-reporting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of BufferGel and 0.5% PRO 2000/5 Gel (P), as assessed by deep epithelial disruption, other genital symptoms, or other systemic symptoms</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV infection as measured by seroconversion</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial vaginosis</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chlamydia infection</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genital ulcer disease</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gonorrhea infection</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Herpes simplex virus-2 infection</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syphilis infection</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trichomoniasis</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of study product</measure>
    <time_frame>At Month 3 and study exit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of behavioral risk assessment questions not answered in self-reported interviews</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of condom use versus gel use</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establishment of a repository of vaginal swab specimens for long-term storage and future research testing on biomarkers of microbicide safety and effectiveness</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3101</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BufferGel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pro 2000/5 Gel (P)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placeo Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BufferGel</intervention_name>
    <description>Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO 2000/5 Gel</intervention_name>
    <description>Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Note: Per the 12/15/06 amendment, all study participants will now enter the Phase IIb
        study.

        Inclusion Criteria:

          -  HIV uninfected

          -  Have had sexual intercourse at least once in the 3 months prior to study entry

          -  Able to provide adequate contact information to study officials for purposes of
             follow-up

        Exclusion Criteria:

          -  History of adverse reaction to latex

          -  Nonmedical injection drug use in the 12 months prior to study entry

          -  Vaginal intercourse more than an average of two times per day in the 2 weeks prior to
             study entry

          -  Plan to become pregnant in the 30 months after study entry

          -  Plan to travel away from the study site for more than 3 consecutive months in the 30
             months after study entry

          -  Plan to relocate away from the study site in the 30 months after study entry

          -  Participation in another clinical trial of a vaginal product

          -  Pregnant within 42 days of study entry

          -  Have a sexually transmitted disease or other reproductive tract infection diagnosed by
             study staff

          -  Abnormal pelvic exam indicating deep epithelial disruption

          -  Condition that, in the opinion of the investigator, may interfere with the study

          -  Liver or kidney function abnormality of Grade 3 or higher

          -  Blood or blood clotting abnormality of Grade 4 or higher
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salim Abdool Karim, MBChB, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of KwaZulu-Natal, Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irving Hoffman, PA, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>School of Medicine, University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Maslankowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Groesbeck Parham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Infectious Disease Research in Zambia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Padian, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco; AIDS Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gita Ramjee, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Research Council, HIV Prevention Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taha Taha, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>3535 Market Street CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lilongwe CRS</name>
      <address>
        <city>Lilongwe</city>
        <state>Central</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Med. JHU CRS</name>
      <address>
        <city>Blantyre</city>
        <state>Southern</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatsworth CRS</name>
      <address>
        <city>Chatsworth</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Research Council-Hlabisa</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamwala Clinic CRS</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke South CRS</name>
      <address>
        <city>Chitungwiza</city>
        <zip>263</zip>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spilhaus CRS</name>
      <address>
        <city>Harare</city>
        <zip>263</zip>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>South Africa</country>
    <country>United States</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Tanzania</country>
  </removed_countries>
  <reference>
    <citation>Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis. 2001 Feb 1;32(3):476-82. Epub 2001 Jan 26.</citation>
    <PMID>11170957</PMID>
  </reference>
  <reference>
    <citation>van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):21-7.</citation>
    <PMID>11176265</PMID>
  </reference>
  <reference>
    <citation>Clarke JG, Peipert JF, Hillier SL, Heber W, Boardman L, Moench TR, Mayer K. Microflora changes with the use of a vaginal microbicide. Sex Transm Dis. 2002 May;29(5):288-93.</citation>
    <PMID>11984446</PMID>
  </reference>
  <reference>
    <citation>Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter III AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, Van Damme L, Celum CL. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):476-83. Erratum in: J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):118.</citation>
    <PMID>12869836</PMID>
  </reference>
  <reference>
    <citation>Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z; HIV Prevention Trials Network (HPTN) 020 Protocol Team. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS. 2003 Feb 14;17(3):321-9.</citation>
    <PMID>12556685</PMID>
  </reference>
  <reference>
    <citation>D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des. 2004;10(3):315-36. Review.</citation>
    <PMID>14754390</PMID>
  </reference>
  <results_reference>
    <citation>MacQueen KM, Namey E, Chilongozi DA, Mtweve SP, Mlingo M, Morar N, Reid C, Ristow A, Sahay S; HPTN 035 Standard of Care Assessment Team. Community perspectives on care options for HIV prevention trial participants. AIDS Care. 2007 Apr;19(4):554-60.</citation>
    <PMID>17453597</PMID>
  </results_reference>
  <results_reference>
    <citation>Minces LR, McGowan I. Advances in the Development of Microbicides for the Prevention of HIV Infection. Curr Infect Dis Rep. 2010 Jan;12(1):56-62. doi: 10.1007/s11908-009-0076-5.</citation>
    <PMID>20368766</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, MÃ¢sse B, Hillier SL, Soto-Torres L; HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011 Apr 24;25(7):957-66. doi: 10.1097/QAD.0b013e32834541d9.</citation>
    <PMID>21330907</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2003</study_first_submitted>
  <study_first_submitted_qc>December 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2003</study_first_posted>
  <disposition_first_submitted>August 24, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 24, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 26, 2009</disposition_first_posted>
  <last_update_submitted>July 5, 2013</last_update_submitted>
  <last_update_submitted_qc>July 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>Anti-Infective Agents, Local</keyword>
  <keyword>BufferGel</keyword>
  <keyword>PRO 2000</keyword>
  <keyword>Vagina</keyword>
  <keyword>Risk Factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

